Autolus Therapeutics (AUTL) CTO reports detailed equity holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc filed an initial ownership report for Chief Technology Officer Neville Miranda Suzette. The filing shows direct ownership of 23,720 American Depositary Shares, each convertible into one ordinary share. Suzette also holds multiple share options to buy ADS at exercise prices between $1.46 and $16.02 expiring from 2030 to 2036, plus 83,300 restricted share units that vest in four equal annual installments starting on January 26, 2027, each RSU representing one ADS.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Neville Miranda Suzette
Role
Chief Technology Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 23,720 shares (Direct);
Share Option (right to buy) — 15,000 shares (Direct);
Restricted Share Units — 83,300 shares (Direct)
Footnotes (1)
- Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. Fully vested and exercisable. This option vested 25% on July 22, 2023 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on February 23, 2025 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on October 8, 2026 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
FAQ
What does the Autolus (AUTL) Form 3 filing disclose about insider holdings?
The Form 3 shows Autolus CTO Neville Miranda Suzette’s existing equity stake, including 23,720 American Depositary Shares, multiple share option awards with various exercise prices and maturities, and 83,300 restricted share units that convert into ADS over time as they vest.
What equity option awards are reported for the Autolus (AUTL) CTO?
The filing lists several share options to buy American Depositary Shares, with exercise prices ranging from $1.46 to $16.02 and expirations between 2030 and 2036. Individual grants include, for example, 375,000 ADS at $1.46 and 250,000 ADS at $1.73 per share.
Does the Autolus (AUTL) Form 3 show any insider buying or selling activity?
The Form 3 is an initial ownership report and does not show new purchases or sales. Instead, it summarizes the CTO’s existing direct ADS holdings, outstanding share options, and unvested restricted share units as of the reporting date, without recording transactional changes.